Blurbs

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), MacroGenics (MGNX) and Axsome Therapeutics (AXSM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Belite Bio, Inc. ADR (BLTEResearch Report), MacroGenics (MGNXResearch Report) and Axsome Therapeutics (AXSMResearch Report) with bullish sentiments.

Belite Bio, Inc. ADR (BLTE)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Belite Bio, Inc. ADR today and set a price target of $58.00. The company’s shares closed last Monday at $26.84.

According to TipRanks.com, Chen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.4% and a 33.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Belite Bio, Inc. ADR with a $57.50 average price target.

See today’s best-performing stocks on TipRanks >>

MacroGenics (MGNX)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on MacroGenics, with a price target of $35.00. The company’s shares closed last Monday at $3.80, close to its 52-week low of $2.13.

According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of -17.7% and a 26.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.

MacroGenics has an analyst consensus of Strong Buy, with a price target consensus of $12.86, representing a 221.5% upside. In a report issued on August 9, Barclays also maintained a Buy rating on the stock with a $8.00 price target.

Axsome Therapeutics (AXSM)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics today and set a price target of $210.00. The company’s shares closed last Monday at $64.46.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -31.8% and a 20.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Aquestive Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $85.70 average price target, representing a 44.0% upside. In a report issued on August 10, Cantor Fitzgerald also maintained a Buy rating on the stock with a $54.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BLTE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos